

Drug Utilization Review Board Meeting			
September 20, 2012			
Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
<b>New Drug Reviews</b>			
Long-Acting Beta-Agonist			
	Arcapta	NP/PA	NP/PA
Antineoplastics			
	Erivedge	P/PA	P/PA
	Inlyta	P/PA	P/PA
Respiratory Agent - Miscellaneous			
	Kalydeco	P/PA	P/PA
Anticonvulsant			
	Onfi	P/PA	P/PA*
*prior authorization for diagnosis, trial of clonazepam and trial of one other agent for Lennox-Gastaut Syndrome			
Topical Antineoplastic			
	Picato	NP/PA	NP/PA
Zyclara changes from P/PA status to NP/PA status.			
Topical Anorectal			
	Rectiv	NP/PA	NP/PA
Ophthalmic Prostaglandin			
	Zioptan	NP/PA	NP/PA

### **Class Reviews**

#### Antihyperkinesia Agents

No changes from the current PDL status.

#### Long-Acting Beta-Agonist Inhalers

No changes from the current PDL status.

#### Statins

Crestor changes from P/PA status to NP/PA status. No changes from the current PDL status for all other agents.